Wells Fargo analyst Derek Archila maintained a Hold rating on Sutro Biopharma (STRO – Research Report) yesterday and set a price target of $5.00. The company’s shares closed yesterday at $3.93.
According to TipRanks, Archila is a 4-star analyst with an average return of 6.4% and a 41.99% success rate. Archila covers the Healthcare sector, focusing on stocks such as Argenx Se, Ascendis Pharma, and Celldex.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $11.44 average price target.
Based on Sutro Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $113.72 million and a net profit of $31.07 million. In comparison, last year the company earned a revenue of $8.63 million and had a GAAP net loss of $34.59 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sutro Biopharma (STRO) Company Description:
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
Read More on STRO:
- Sutro Biopharma reports Q1 EPS (95c), consensus (92c)
- Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- STRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lululemon initiated, Block upgraded: Wall Street’s top analyst calls
- Sutro initiated with Buy on ovarian cancer potential at BofA
